Replimune Group, Inc. Stock

$9.58

1.86%

Nasdaq, Jul 07, 03:49 pm CET

ISIN

US76029N1063

Symbol

REPL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Replimune Group, Inc. Stock price

$9.40

-12.76 57.58% 5Y

Nasdaq, Closing price Thu, Jul 03 2025

-0.15 1.57%

ISIN

US76029N1063

Symbol

REPL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$724.6m

Enterprise Value

$312.7m

Net debt

positive

Cash

$483.8m

Shares outstanding

77.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 28.3

EV/Sales

- | 12.2

EV/FCF

negative

P/B

1.7

Financial Health

Equity Ratio

75.4%

Return on Equity

-59.5%

ROCE

-53.5%

ROIC

-535.1%

Debt/Equity

0.2

Financials (TTM | estimate)

Revenue

$0.0 | $25.6m

EBITDA

$-259.2m | $-244.8m

EBIT

$-261.6m | $-263.9m

Net Income

$-247.3m | $-243.5m

Free Cash Flow

$-198.9m

EPS

$-2.7

FCF per Share

$-2.6

Short interest

16.7%

Employees

331

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Replimune Group, Inc. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Replimune Group, Inc. forecast:

14x Buy

93%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Replimune Group, Inc. forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Replimune Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	73 73	22% 22% -
- Research and Development Expense	186 186	8% 8% -
EBITDA	-259 -259	12% 12% -
- Depreciation and Amortization	2.43 2.43	0% 0% -
EBIT (Operating Income) EBIT	-262 -262	11% 11% -
Net Profit	-247 -247	15% 15% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Replimune Group, Inc. Stock News

Neutral

GlobeNewsWire

●

about one month ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

Neutral

GlobeNewsWire

●

about one month ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology...

Neutral

GlobeNewsWire

●

about one month ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET.

More Replimune Group, Inc. News

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Head office	United States
CEO	Sushil Patel
Employees	331
Founded	2015
Website	www.replimune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now